MA50397A - Anticorps anti-tau et leurs utilisations - Google Patents

Anticorps anti-tau et leurs utilisations

Info

Publication number: MA50397A
Authority: MA; Morocco
Prior art keywords: tau; body anti
Prior art date: 2017-10-16

Application number

MA050397A

Other languages

English (en)

Inventor

Kishan Agarwala

Shigeru Akasofu

Hirofumi Aoyagi

Silva Hettihewage Alfred Rohan De

Yutaka Hashizume

Malcolm Ian Roberts

Jared Spidel

James Martin Staddon

Original Assignee

Eisai R&D Man Co Ltd

Ucl Business Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-16

Filing date

2018-10-16

Publication date

2020-08-26

2018-10-16 Application filed by Eisai R&D Man Co Ltd, Ucl Business Ltd filed Critical Eisai R&D Man Co Ltd

2020-08-26 Publication of MA50397A publication Critical patent/MA50397A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

MA050397A 2017-10-16 2018-10-16 Anticorps anti-tau et leurs utilisations MA50397A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201762572910P	2017-10-16	2017-10-16
US201762577011P	2017-10-25	2017-10-25
US201862697034P	2018-07-12	2018-07-12

Publications (1)

Publication Number	Publication Date
MA50397A true MA50397A (fr)	2020-08-26

Family

ID=64100697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050397A MA50397A (fr)	2017-10-16	2018-10-16	Anticorps anti-tau et leurs utilisations

Country Status (20)

Country	Link
US (4)	US10829547B2 (fr)
EP (1)	EP3697814A1 (fr)
JP (2)	JP6851549B2 (fr)
KR (2)	KR102225178B1 (fr)
CN (1)	CN111630064B (fr)
AU (1)	AU2018352308A1 (fr)
BR (1)	BR112020007536A2 (fr)
CA (1)	CA3077247A1 (fr)
CL (3)	CL2020001003A1 (fr)
CO (1)	CO2020005981A2 (fr)
IL (2)	IL273832B (fr)
JO (1)	JOP20200074A1 (fr)
MA (1)	MA50397A (fr)
MX (1)	MX2020003857A (fr)
PE (2)	PE20210115A1 (fr)
PH (1)	PH12020550243A1 (fr)
SG (1)	SG11202003392VA (fr)
TW (3)	TWI750419B (fr)
WO (1)	WO2019077500A1 (fr)
ZA (1)	ZA202001548B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2014248515B2 (en)	2013-03-13	2019-03-07	Prothena Biosciences Limited	Tau immunotherapy
KR102471787B1 (ko)	2016-05-02	2022-11-29	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
ES2933491T3 (es)	2016-05-02	2023-02-09	Prothena Biosciences Ltd	Inmunoterapia tau
EP3583123A1 (fr)	2017-02-17	2019-12-25	Denali Therapeutics Inc.	Anticorps anti-tau et leurs procédés d'utilisation
CA3061516A1 (fr)	2017-05-02	2018-11-08	Prothena Biosciences Limited	Anticorps reconnaissant la proteine tau
TWI750419B (zh) *	2017-10-16	2021-12-21	日商衛材R&D企管股份有限公司	抗tau抗體及其用途
WO2020180819A1 (fr)	2019-03-03	2020-09-10	Prothena Biosciences Limited	Anticorps reconnaissant la protéine tau
CN116096751A (zh) *	2020-02-25	2023-05-09	璟尚生物制药公司	三特异性t细胞接合器
US20220064271A1 (en) *	2020-09-01	2022-03-03	Washington University	Methods for treating tauopathies
AU2022307687A1 (en)	2021-07-09	2024-01-04	Eisai R&D Management Co., Ltd.	Biomarkers for alzheimer's disease treatment
WO2023079485A1 (fr)	2021-11-03	2023-05-11	Eisai R&D Management Co., Ltd.	Compositions d'anticorps anti-tau, formes galéniques et méthodes
WO2023092004A1 (fr)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions et méthodes pour le traitement de troubles liés à tau
WO2023111618A1 (fr)	2021-12-17	2023-06-22	Eisai R&D Management Co., Ltd.	Méthodes d'utilisation d'un anticorps anti-amyloïde à protofibrille bêta et d'un anticorps anti-tau
WO2023114586A1 (fr)	2021-12-17	2023-06-22	Eisai R&D Management Co., Ltd.	Procédés d'utilisation d'un anticorps anti-protofibrille bêta-amyloïde et d'un anticorps anti-tau
WO2023149970A1 (fr)	2022-02-02	2023-08-10	Eisai R&D Management Co., Ltd.	Méthodes de traitement utilisant le niveau de p-tau181

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
AU2008338313B2 (en)	2007-12-18	2014-01-16	Bioalliance C.V.	Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
UA107571C2 (xx)	2009-04-03	2015-01-26		Фармацевтична композиція
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3120504A1 (fr)	2009-06-10	2010-12-16	New York University	Ciblage immunologique de proteines tau pathologiques
TW201216985A (en)	2010-10-07	2012-05-01	Ac Immune Sa	Pharmaceutical composition
JP2014503178A (ja)	2010-10-11	2014-02-13	バイオジェンアイデックインターナショナルニューロサイエンスゲーエムベーハー	ヒト抗タウ抗体
CA2829223A1 (fr)	2011-03-11	2012-09-20	Beka Solomon	Methode de traitement de tauopathie neurodegenerative
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
SG10201912964PA (en) *	2011-09-19	2020-02-27	Axon Neuroscience Se	Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
JP6306513B2 (ja)	2011-12-20	2018-04-04	ヤンセンバイオテツク，インコーポレーテツド	抗ＰＨＦ−ｔａｕ抗体及びその使用
MX356800B (es) *	2012-04-05	2018-06-13	Ac Immune Sa	Anticuerpo tau humanizado.
WO2013177104A2 (fr)	2012-05-21	2013-11-28	Felder Mitchell S	Traitement de tauopathies
DK2857039T3 (da)	2012-05-31	2019-12-16	Univ Osaka City	Terapeutisk middel eller profylaktisk middel mod demens
CN104781278B (zh) *	2012-07-03	2018-06-12	华盛顿大学	针对tau的抗体
MX359817B (es)	2012-08-16	2018-10-11	Ipierian Inc	Anticuerpos que se enlazan a tau.
EP2906596B1 (fr)	2012-10-12	2023-12-27	Arizona Board of Regents on behalf of Arizona State University	Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2014089104A1 (fr)	2012-12-03	2014-06-12	Washington University	Procédé de détection d'agrégats dans des échantillons biologiques
WO2014096321A1 (fr)	2012-12-21	2014-06-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps spécifiques de la protéine tau phosphorylée à la sérine 422 et leurs utilisations pour traiter et diagnostiquer les tauopathies
EA035932B1 (ru)	2012-12-21	2020-09-02	Байоджен Ма Инк.	Человеческие анти-тау антитела
AU2014248515B2 (en)	2013-03-13	2019-03-07	Prothena Biosciences Limited	Tau immunotherapy
MX2015012872A (es)	2013-03-15	2016-02-03	Ac Immune Sa	Anticuerpos anti-tau y metodos de uso.
SG11201509982UA (fr)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
PL3007726T3 (pl)	2013-06-10	2021-01-11	Ipierian, Inc.	Metody leczenia tauopatii
GB201312226D0 (en)	2013-07-08	2013-08-21	Adx Neurosciences	Improved antibodies
PL3083680T3 (pl)	2013-12-20	2020-06-29	F. Hoffmann-La Roche Ag	Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
CN106165294B (zh)	2014-05-07	2019-01-11	株式会社村田制作所	声表面波装置
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CN107074935B (zh)	2014-06-26	2021-08-03	扬森疫苗与预防公司	特异性结合微管相关蛋白tau的抗体和抗原结合片段
TWI664190B (zh) *	2014-06-27	2019-07-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗－ｔａｕ抗體
DE102014013571A1 (de)	2014-09-18	2016-03-24	Aj Roboscreen Gmbh	Monoklonaler Antikörper gegen humanes TAU-Protein
EP3786182A1 (fr) *	2014-11-19	2021-03-03	Axon Neuroscience SE	Anticorps anti-tau humanisés dans la maladie d'alzheimer
AU2015353585A1 (en)	2014-11-25	2017-06-01	Abbott Diabetes Care Inc.	Analyte monitoring systems and related test and monitoring methods
WO2016112078A2 (fr)	2015-01-08	2016-07-14	Janssen Biotech, Inc.	Anticorps tau/anti-phf et leurs utilisations
WO2016137950A1 (fr)	2015-02-24	2016-09-01	Rpeptide, Llc	Anticorps anti-tau
AR103713A1 (es) *	2015-02-26	2017-05-31	Lilly Co Eli	Anticuerpos contra tau y sus usos
CN107849124B (zh)	2015-06-05	2021-09-24	基因泰克公司	抗tau抗体及使用方法
MA41669A1 (fr)	2015-07-06	2018-05-31	Ucb Biopharma Sprl	Anticorps se liant a tau
US10287343B2 (en)	2015-07-06	2019-05-14	Ucb Biopharma Sprl	Tau-binding antibodies
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) *	2015-08-27	2017-07-11	Taiwan Semiconductor Manufacturing Company, Ltd.	Deep trench isolation structures and methods of forming same
US20190194345A1 (en)	2015-10-05	2019-06-27	University Of Virginia Patent Foundation	Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
CN117069841A (zh) *	2015-10-06	2023-11-17	艾利妥	抗trem2抗体及其使用方法
KR102471787B1 (ko)	2016-05-02	2022-11-29	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
CN109415434B (zh)	2016-05-02	2022-12-30	普罗塞纳生物科学有限公司	识别tau的抗体
MY197836A (en)	2016-07-12	2023-07-20	H Lundbeck As	Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3583123A1 (fr) *	2017-02-17	2019-12-25	Denali Therapeutics Inc.	Anticorps anti-tau et leurs procédés d'utilisation
JP2018139530A (ja)	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar)	2017-03-16	2019-01-30	Janssen Biotech Inc	الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CA3061516A1 (fr) *	2017-05-02	2018-11-08	Prothena Biosciences Limited	Anticorps reconnaissant la proteine tau
TWI750419B (zh)	2017-10-16	2021-12-21	日商衛材R&D企管股份有限公司	抗tau抗體及其用途

2018
- 2018-10-16 TW TW107136326A patent/TWI750419B/zh active
- 2018-10-16 AU AU2018352308A patent/AU2018352308A1/en active Pending
- 2018-10-16 US US16/161,586 patent/US10829547B2/en active Active
- 2018-10-16 KR KR1020207011600A patent/KR102225178B1/ko active IP Right Grant
- 2018-10-16 PE PE2020000397A patent/PE20210115A1/es unknown
- 2018-10-16 BR BR112020007536-1A patent/BR112020007536A2/pt unknown
- 2018-10-16 SG SG11202003392VA patent/SG11202003392VA/en unknown
- 2018-10-16 TW TW112123476A patent/TW202340244A/zh unknown
- 2018-10-16 JO JOP/2020/0074A patent/JOP20200074A1/ar unknown
- 2018-10-16 TW TW110142156A patent/TWI809562B/zh active
- 2018-10-16 PE PE2021000519A patent/PE20212088A1/es unknown
- 2018-10-16 KR KR1020207011686A patent/KR20200058480A/ko not_active Application Discontinuation
- 2018-10-16 EP EP18796772.4A patent/EP3697814A1/fr active Pending
- 2018-10-16 WO PCT/IB2018/058024 patent/WO2019077500A1/fr unknown
- 2018-10-16 JP JP2020518723A patent/JP6851549B2/ja active Active
- 2018-10-16 MA MA050397A patent/MA50397A/fr unknown
- 2018-10-16 MX MX2020003857A patent/MX2020003857A/es unknown
- 2018-10-16 CN CN201880066003.1A patent/CN111630064B/zh active Active
- 2018-10-16 CA CA3077247A patent/CA3077247A1/fr active Pending
- 2018-12-12 US US16/217,360 patent/US10358485B2/en active Active
2020
- 2020-03-11 ZA ZA2020/01548A patent/ZA202001548B/en unknown
- 2020-04-06 IL IL273832A patent/IL273832B/en unknown
- 2020-04-08 PH PH12020550243A patent/PH12020550243A1/en unknown
- 2020-04-15 CL CL2020001003A patent/CL2020001003A1/es unknown
- 2020-05-15 CO CONC2020/0005981A patent/CO2020005981A2/es unknown
- 2020-09-24 US US17/030,655 patent/US11578120B2/en active Active
2021
- 2021-03-02 CL CL2021000517A patent/CL2021000517A1/es unknown
- 2021-03-02 CL CL2021000516A patent/CL2021000516A1/es unknown
- 2021-03-09 JP JP2021037603A patent/JP7223794B2/ja active Active
2022
- 2022-02-21 IL IL290783A patent/IL290783A/en unknown
2023
- 2023-01-04 US US18/149,905 patent/US20240034777A1/en active Pending

Also Published As

Publication number	Publication date
KR20200051035A (ko)	2020-05-12
CN111630064A (zh)	2020-09-04
IL273832B (en)	2022-06-01
ZA202001548B (en)	2021-10-27
AU2018352308A1 (en)	2020-03-19
KR102225178B1 (ko)	2021-03-10
US10829547B2 (en)	2020-11-10
WO2019077500A1 (fr)	2019-04-25
CO2020005981A2 (es)	2020-07-31
US10358485B2 (en)	2019-07-23
SG11202003392VA (en)	2020-05-28
TW202207985A (zh)	2022-03-01
BR112020007536A2 (pt)	2020-09-29
US20210024622A1 (en)	2021-01-28
TWI750419B (zh)	2021-12-21
EP3697814A1 (fr)	2020-08-26
JP2020536534A (ja)	2020-12-17
US20190112365A1 (en)	2019-04-18
PH12020550243A1 (en)	2021-02-15
RU2020115817A (ru)	2021-11-18
IL273832A (en)	2020-05-31
CL2021000516A1 (es)	2021-09-24
CN111630064B (zh)	2023-06-27
MX2020003857A (es)	2021-01-08
PE20210115A1 (es)	2021-01-19
PE20212088A1 (es)	2021-11-04
JP2021097698A (ja)	2021-07-01
KR20200058480A (ko)	2020-05-27
CL2020001003A1 (es)	2020-10-02
JOP20200074A1 (ar)	2020-04-30
US20190112364A1 (en)	2019-04-18
US11578120B2 (en)	2023-02-14
RU2020115817A3 (fr)	2022-04-08
TW201927817A (zh)	2019-07-16
JP6851549B2 (ja)	2021-03-31
CL2021000517A1 (es)	2021-09-24
TW202340244A (zh)	2023-10-16
JP7223794B2 (ja)	2023-02-16
CA3077247A1 (fr)	2019-04-25
TWI809562B (zh)	2023-07-21
US20240034777A1 (en)	2024-02-01
IL290783A (en)	2022-04-01

Publication	Publication Date	Title
MA50397A (fr)	2020-08-26	Anticorps anti-tau et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
MA45235A (fr)	2019-04-17	Anticorps anti-c5 et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
MA50144A (fr)	2020-07-29	Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA42935A (fr)	2018-08-01	Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA46041A (fr)	2021-03-24	Anticorps anti-tim -3
MA52773A (fr)	2021-04-14	Anticorps anti-cd3 et leurs utilisations
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA51287A (fr)	2021-03-31	Analogues d'incrétine et leurs utilisations
MA46471A (fr)	2021-05-19	Protéines actriib à variant et leurs utilisations
MA43567A (fr)	2018-11-14	Anticorps pacap et leurs utilisations
MA45233A (fr)	2019-04-17	Anticorps anti-gitr et leurs utilisations
MA45231A (fr)	2021-05-05	Anticorps anti-ige
MA52949A (fr)	2021-04-28	Anticorps anti-pd-1 et leurs utilisations
MA44665A (fr)	2019-02-20	Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques